Outcomes from this study suggested that restoring the balance of downstream TGF-β/Smad signaling with AA (a Smad7 agonist) and NG (a Smad3 inhibitor) may represent a new therapeutic approach for chronic kidney disease associated with progressive renal fibrosis. Here, SMAD3 is linked to renal fibrosis.